Glofitamab
Roche
['lymsm']
glofi monotherapy follow-up #17icml:
- orr 52%, cr 40%
- mdocr 27 mos
- mpfs/os much worse if less than cr
- 6% gr5 aes (causes not defined)
common thread with bites: patients with cr continue to do well. #lymsm 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈